# US 2005/0032703 A1 · Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032703 A1
- Document ID: US20050032703A1
- Status: Published application
- Kind: A1
- Application number: 10/940,498
- Filed: 2004-09-13
- Published: 2005-02-10
- Earliest claimed: 2001-04-04
- Assignees: American Diagnostic, Inc.
- Inventors: Robert Greenfield; Seong Soo An
- Web page: https://patentgrep.com/patent/US20050032703A1

## CPC

- C12N 9/48: acting on peptide bonds (3.4)
- A61K 38/05: Dipeptides
- A61K 38/363: {Fibrinogen}
- A61K 38/49: Urokinase; Tissue plasminogen activator
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- Y10S 435/975: Kit
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention is directed in part to a purified form of stabilized activated thrombin-activatable fibrinolysis inhibitor (TAFIa). The invention is further directed to a method of producing stabilized TAFIa. The invention is also directed to methods for therapeutic use of stabilized TAFIa such as in the treatment, prevention or management of diseases via an anti-coagulant effect. The invention is also directed to methods for therapeutic use of inhibitors of TAFIa such as in the treatment, prevention or management of diseases via a procoagulant effect. The invention is also directed to methods of diagnostic use of stabilized TAFIa such as a standard in a chromogenic or a fluorometric carboxypeptidase activity assay. The present invention is also directed to kits comprising stabilized TAFIa useful in measuring carboxypepetidase activity.

## Claims

### Claim 1

A method of preparing stabilized TAFIa, said method comprising proteolytic cleavage of TAFI with a protease that cleaves TAFI to TAFIa in a substantially calcium-free environment.

### Claim 2 (depends on 1)

The method of claim 1, wherein the stabilized TAFIa remains stable for at least one hour at 37° C.

### Claim 3 (depends on 1)

The method of claim 1, wherein the stabilized TAFIa remains stable for at least eight hours at 37° C.

### Claim 4 (depends on 1)

The method of claim 1, wherein the TAFI is a wild-type TAFI protein.

### Claim 5 (depends on 4)

The method of claim 4, wherein the TAFI is recombinantly produced.

### Claim 6 (depends on 1)

The method of claim 1, wherein the TAFI is a mutant TAFI protein.

### Claim 7 (depends on 1)

The method of claim 1, wherein there is less than 1 mM calcium present.

### Claim 8 (depends on 1)

The method of claim 1, wherein the protease is thrombin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the protease is a thrombin-thrombomodulin complex.

### Claim 10 (depends on 1)

The method of claim 1, wherein the protease is plasmin.
